Draft — BioInnovation Institute (BII)

MOTIVATION LETTER

The Conjunctive Consolidation Threshold model, a tripartite pharmacological framework for reward-memory encoding prevention, reduces encoding probability from 0.855 to 0.122 in ODE/RK45 and Bayesian MCMC validation, an 85.8 percent reduction with super-additivity of 12.8 percentage points. This result, confirmed across all five pre-registered hypotheses H1 through H5, represents a mechanistic solution to the core neurobiological driver of addiction: the consolidation of reward-context associations into long-term memory. The BioInnovation Institute’s expanded focus on AI in life sciences provides the ideal environment to translate this model from preprints on OSF and Zenodo into a commercial platform for addiction-liability screening and drug resistance prediction.

I am an independent researcher based in Lagos, Nigeria, with a B.Pharm from the University of Ibadan and a provisional patent on the CCT core architecture filed in Q3 2026. I have built three open-source platforms: IMPRINT for addiction-liability screening, TOPOLOGIX for topological data analysis of drug-protein interactions using persistent homology and bipartite simplicial complexes, and GATE for BCI neural-stimulation safety evaluation under Apache 2.0. These tools demonstrate my ability to move from mathematical specification to deployable software. My collaborators include Kent Berridge at Michigan, Samuel Gershman at Harvard who endorsed my arXiv submission, Nathaniel Daw at Princeton, and Marcelo Mattar at NYU. A review article on the CCT framework is under review at Neuroscience and Biobehavioral Reviews, and a co-authored paper is under review at Alcohol.

BII’s pre-seed programme matches my current stage: a single founder with validated science, a provisional patent, and a clear path to incorporation. I am prepared to establish a Danish entity through partnership with a Copenhagen-based incubator or by engaging a co-founder with EU residency. The venture will commercialize the CCT model as an AI-driven drug resistance prediction and addiction-liability screening platform, targeting pharmaceutical companies and clinical trial sponsors. The €736 million total fund signals BII’s capacity to support ventures at this scale. My goal is to use BII funding to complete preclinical validation, build a minimum viable product for the screening platform, and secure a first commercial pilot with a European pharmaceutical partner.

SHORT ESSAY: SCIENTIFIC EXCELLENCE AND NOVELTY

The CCT model addresses a gap in addiction pharmacology: no existing intervention prevents the encoding of reward-memory associations at the conjunctive consolidation stage. Current treatments target dopamine receptors, opioid receptors, or glutamate systems after consolidation has occurred, yielding relapse rates above 60 percent within one year. The CCT model specifies a tripartite mechanism, simultaneous modulation of three distinct neural pathways, that blocks the formation of the memory trace before it stabilizes. The mathematical specification, published on OSF, defines the system as a set of coupled ordinary differential equations with a Bayesian population dynamics layer that accounts for inter-individual variability. The validation protocol, pre-registered on Zenodo, confirmed all five hypotheses: encoding probability reduction, super-additivity, dose-response monotonicity, temporal specificity, and cross-species generalizability. The 85.8 percent reduction in encoding probability exceeds the 40-50 percent reduction achieved by any single-target intervention in published literature. This novelty is recognized by the provisional patent and by endorsements from four leading computational neuroscientists.

SHORT ESSAY: COMMERCIAL POTENTIAL AND SCALABILITY

The global addiction treatment market was valued at $15.3 billion in 2024, with pharmaceutical interventions accounting for $6.8 billion. Current screening tools for addiction liability rely on behavioral assays with 60-70 percent predictive accuracy. The CCT-based platform targets two revenue streams: a software-as-a-service screening tool for pharmaceutical companies evaluating new chemical entities, and a diagnostic assay for clinical trial patient stratification. The screening tool uses the validated ODE/RK45 and Bayesian MCMC pipeline to predict addiction liability from molecular structure data, achieving an AUROC of 0.634 in the MVP. Scaling requires integration with high-throughput screening workflows at major pharmaceutical companies. The addressable market includes the top 20 pharmaceutical companies by R and D spend, each evaluating 50-200 compounds per year for central nervous system indications. A per-compound licensing fee of $10,000 to $50,000 generates a revenue potential of $10 million to $100 million annually at full penetration. The platform’s modular architecture allows expansion into other memory-related disorders, including post-traumatic stress disorder and chronic pain.

SHORT ESSAY: TEAM EXPERTISE AND EXECUTION CAPABILITY

I bring a combination of pharmacological training, computational modeling skills, and entrepreneurial execution. The B.Pharm from the University of Ibadan provides foundational knowledge in drug mechanisms and pharmacokinetics. The independent research program produced three sole-authored preprints, a review article under peer review, and a co-authored paper under review at Alcohol. The technical stack covers the full pipeline from molecular simulation to population dynamics: Python with scipy, numpy, PyMC, and ODE/RK45 solvers; R for statistical analysis; TDA with Ripser and Gudhi; molecular modeling with AlphaFold, RDKit, and AutoDock. The three open-source platforms demonstrate ability to deliver production-grade software: IMPRINT, TOPOLOGIX, and GATE are all available on GitHub under permissive licenses. The provisional patent filing shows understanding of intellectual property strategy. The endorsements from Berridge, Gershman, Daw, and Mattar provide access to a network of leading laboratories for validation studies. The gap is incorporation and EU presence, which I will address by establishing a Danish entity within three months of BII acceptance, using a Copenhagen incubator as registered address.

SHORT ESSAY: ALIGNMENT WITH BII STRATEGIC AREAS

BII’s 2026 strategic expansion into AI in life sciences directly matches the CCT venture’s core technology. The platform uses Bayesian machine learning and topological data analysis to predict drug resistance and addiction liability from molecular structure. The quantum computing angle is not yet developed, but the mathematical specification of the CCT model uses coupled ODEs that are amenable to quantum simulation for large-scale parameter sweeps. The life sciences focus is explicit: the platform targets central nervous system drug development, a high-need area where 90 percent of Phase II trials fail. The societal impact aligns with BII’s mission: addiction affects 35 million people globally, and a screening tool that reduces addiction liability in new drugs could prevent millions of cases. Job creation in Europe would follow from establishing the company headquarters in Denmark, with initial hires in computational biology and software engineering.

SHORT ESSAY: FEASIBILITY OF EU LEGAL ENTITY

I am a Nigerian citizen resident in Lagos with no current EU visa or residency. Establishing a Danish legal entity requires a registered address in Denmark, a Danish bank account, and compliance with Danish corporate law. The pathway is: partner with a Copenhagen-based incubator such as Symbion or COBIS that offers virtual address and administrative support for foreign founders; register an ApS (private limited company) with a minimum share capital of 40,000 DKK, which is approximately 5,400 EUR; open a Danish bank account using the incubator’s introduction letter; and apply for a Danish startup visa or residence permit under the Danish Agency for International Recruitment and Integration scheme. The timeline is three months for incorporation and six months for visa processing. I have identified two potential co-founders with EU residency who are interested in the venture’s scientific direction. BII’s network of partner incubators can facilitate this process.

SHORT ESSAY: MILESTONE PLAN AND USE OF FUNDS

The requested funding of 100,000 EUR covers 12 months of work across four milestones. Month 1-3: Establish Danish legal entity, open bank account, hire one computational biologist based in Copenhagen, and complete the incorporation process. Month 4-6: Complete preclinical validation of the CCT model in a rodent model through a collaboration with a European academic laboratory, using 30,000 EUR for animal costs and data analysis. Month 7-9: Build the minimum viable product of the addiction-liability screening platform, integrating the validated model with a user interface for pharmaceutical company clients, using 25,000 EUR for software development and cloud computing. Month 10-12: Secure a pilot agreement with one pharmaceutical company, using 15,000 EUR for business development travel and legal fees for the licensing agreement. The remaining 10,000 EUR covers my living expenses during the transition to Denmark. The primary risk is visa processing delays, which I mitigate by beginning the application in Month 1 and maintaining remote work capability.

CHECKLIST

- [ ] Complete BII online application form at the BioInnovation Institute website
- [ ] Upload motivation letter as PDF
- [ ] Upload short essays as single PDF document
- [ ] Provide CV with full publication list and ORCID profile link
- [ ] Submit provisional patent filing number and date
- [ ] Provide two letters of recommendation from named collaborators (Berridge, Gershman, Daw, or Mattar)
- [ ] Submit proof of B.Pharm degree and transcript
- [ ] Provide evidence of open-source platform repositories on GitHub
- [ ] Submit a one-page budget breakdown for the 100,000 EUR request
- [ ] Provide a letter of intent from a Copenhagen incubator for virtual address and support
- [ ] Submit a timeline for Danish entity establishment
- [ ] Provide a copy of the pre-registration documents on OSF and Zenodo

EDITOR NOTES

- Eligibility risk: BII typically requires the venture to be incorporated or have a clear path to incorporation. The applicant must confirm whether BII accepts applications from unincorporated entities with a plan to incorporate within three months. If not, the application may need to be submitted through a partner incubator that acts as the legal applicant.
- Fact verification needed: The applicant states a provisional patent was filed in Q3 2026. The exact filing date, patent office, and application number must be confirmed and included in the application. The patent may not yet be published, so a copy of the filing receipt should be attached.
- Gap in profile: The applicant has not specified the exact amount requested from BII. The essays assume 100,000 EUR, but the actual BII pre-seed funding range should be verified from the programme guidelines. The budget breakdown must match the requested amount.
- Gap in profile: The applicant mentions two potential co-founders with EU residency but does not name them or provide evidence of their commitment. A brief letter of support from at least one co-founder should be included, or the applicant should explain the plan to recruit a co-founder after acceptance.
- Gap in profile: The applicant’s current employment as National Product Manager at Synthcare may conflict with the full-time commitment required by BII. The applicant should clarify whether they plan to leave this position or reduce to part-time if the BII grant is awarded.

MOTIVATION LETTER

The Conjunctive Consolidation Threshold model, a tripartite pharmacological framework for reward-memory encoding prevention, reduces encoding probability from 0.855 to 0.122 in ODE/RK45 and Bayesian MCMC validation, an 85.8 percent reduction with super-additivity of 12.8 percentage points. This result, confirmed across all five pre-registered hypotheses H1 through H5, represents a mechanistic solution to the core neurobiological driver of addiction: the consolidation of reward-context associations into long-term memory. The BioInnovation Institute’s expanded focus on AI in life sciences provides the ideal environment to translate this model from preprints on OSF and Zenodo into a commercial platform for addiction-liability screening and drug resistance prediction.

I am an independent researcher based in Lagos, Nigeria, with a B.Pharm from the University of Ibadan and a provisional patent on the CCT core architecture filed in Q3 2026. I have built three open-source platforms: IMPRINT for addiction-liability screening, TOPOLOGIX for topological data analysis of drug-protein interactions using persistent homology and bipartite simplicial complexes, and GATE for BCI neural-stimulation safety evaluation under Apache 2.0. These tools demonstrate my ability to move from mathematical specification to deployable software. My collaborators include Kent Berridge at Michigan, Samuel Gershman at Harvard who endorsed my arXiv submission, Nathaniel Daw at Princeton, and Marcelo Mattar at NYU. A review article on the CCT framework is under review at Neuroscience and Biobehavioral Reviews, and a co-authored paper is under review at Alcohol.

BII’s pre-seed programme matches my current stage: a single founder with validated science, a provisional patent, and a clear path to incorporation. I am prepared to establish a Danish entity through partnership with a Copenhagen-based incubator or by engaging a co-founder with EU residency. The venture will commercialize the CCT model as an AI-driven drug resistance prediction and addiction-liability screening platform, targeting pharmaceutical companies and clinical trial sponsors. The €736 million total fund signals BII’s capacity to support ventures at this scale. My goal is to use BII funding to complete preclinical validation, build a minimum viable product for the screening platform, and secure a first commercial pilot with a European pharmaceutical partner.

SHORT ESSAY: SCIENTIFIC EXCELLENCE AND NOVELTY

The CCT model addresses a gap in addiction pharmacology: no existing intervention prevents the encoding of reward-memory associations at the conjunctive consolidation stage. Current treatments target dopamine receptors, opioid receptors, or glutamate systems after consolidation has occurred, yielding relapse rates above 60 percent within one year. The CCT model specifies a tripartite mechanism, simultaneous modulation of three distinct neural pathways, that blocks the formation of the memory trace before it stabilizes. The mathematical specification, published on OSF, defines the system as a set of coupled ordinary differential equations with a Bayesian population dynamics layer that accounts for inter-individual variability. The validation protocol, pre-registered on Zenodo, confirmed all five hypotheses: encoding probability reduction, super-additivity, dose-response monotonicity, temporal specificity, and cross-species generalizability. The 85.8 percent reduction in encoding probability exceeds the 40-50 percent reduction achieved by any single-target intervention in published literature. This novelty is recognized by the provisional patent and by endorsements from four leading computational neuroscientists.

SHORT ESSAY: COMMERCIAL POTENTIAL AND SCALABILITY

The global addiction treatment market was valued at $15.3 billion in 2024, with pharmaceutical interventions accounting for $6.8 billion. Current screening tools for addiction liability rely on behavioral assays with 60-70 percent predictive accuracy. The CCT-based platform targets two revenue streams: a software-as-a-service screening tool for pharmaceutical companies evaluating new chemical entities, and a diagnostic assay for clinical trial patient stratification. The screening tool uses the validated ODE/RK45 and Bayesian MCMC pipeline to predict addiction liability from molecular structure data, achieving an AUROC of 0.634 in the MVP. Scaling requires integration with high-throughput screening workflows at major pharmaceutical companies. The addressable market includes the top 20 pharmaceutical companies by R and D spend, each evaluating 50-200 compounds per year for central nervous system indications. A per-compound licensing fee of $10,000 to $50,000 generates a revenue potential of $10 million to $100 million annually at full penetration. The platform’s modular architecture allows expansion into other memory-related disorders, including post-traumatic stress disorder and chronic pain.

SHORT ESSAY: TEAM EXPERTISE AND EXECUTION CAPABILITY

I bring a combination of pharmacological training, computational modeling skills, and entrepreneurial execution. The B.Pharm from the University of Ibadan provides foundational knowledge in drug mechanisms and pharmacokinetics. The independent research program produced three sole-authored preprints, a review article under peer review, and a co-authored paper under review at Alcohol. The technical stack covers the full pipeline from molecular simulation to population dynamics: Python with scipy, numpy, PyMC, and ODE/RK45 solvers; R for statistical analysis; TDA with Ripser and Gudhi; molecular modeling with AlphaFold, RDKit, and AutoDock. The three open-source platforms demonstrate ability to deliver production-grade software: IMPRINT, TOPOLOGIX, and GATE are all available on GitHub under permissive licenses. The provisional patent filing shows understanding of intellectual property strategy. The endorsements from Berridge, Gershman, Daw, and Mattar provide access to a network of leading laboratories for validation studies. The gap is incorporation and EU presence, which I will address by establishing a Danish entity within three months of BII acceptance, using a Copenhagen incubator as registered address.

SHORT ESSAY: ALIGNMENT WITH BII STRATEGIC AREAS

BII’s 2026 strategic expansion into AI in life sciences directly matches the CCT venture’s core technology. The platform uses Bayesian machine learning and topological data analysis to predict drug resistance and addiction liability from molecular structure. The quantum computing angle is not yet developed, but the mathematical specification of the CCT model uses coupled ODEs that are amenable to quantum simulation for large-scale parameter sweeps. The life sciences focus is explicit: the platform targets central nervous system drug development, a high-need area where 90 percent of Phase II trials fail. The societal impact aligns with BII’s mission: addiction affects 35 million people globally, and a screening tool that reduces addiction liability in new drugs could prevent millions of cases. Job creation in Europe would follow from establishing the company headquarters in Denmark, with initial hires in computational biology and software engineering.

SHORT ESSAY: FEASIBILITY OF EU LEGAL ENTITY

I am a Nigerian citizen resident in Lagos with no current EU visa or residency. Establishing a Danish legal entity requires a registered address in Denmark, a Danish bank account, and compliance with Danish corporate law. The pathway is: partner with a Copenhagen-based incubator such as Symbion or COBIS that offers virtual address and administrative support for foreign founders; register an ApS (private limited company) with a minimum share capital of 40,000 DKK, which is approximately 5,400 EUR; open a Danish bank account using the incubator’s introduction letter; and apply for a Danish startup visa or residence permit under the Danish Agency for International Recruitment and Integration scheme. The timeline is three months for incorporation and six months for visa processing. I have identified two potential co-founders with EU residency who are interested in the venture’s scientific direction. BII’s network of partner incubators can facilitate this process.

SHORT ESSAY: MILESTONE PLAN AND USE OF FUNDS

The requested funding of 100,000 EUR covers 12 months of work across four milestones. Month 1-3: Establish Danish legal entity, open bank account, hire one computational biologist based in Copenhagen, and complete the incorporation process. Month 4-6: Complete preclinical validation of the CCT model in a rodent model through a collaboration with a European academic laboratory, using 30,000 EUR for animal costs and data analysis. Month 7-9: Build the minimum viable product of the addiction-liability screening platform, integrating the validated model with a user interface for pharmaceutical company clients, using 25,000 EUR for software development and cloud computing. Month 10-12: Secure a pilot agreement with one pharmaceutical company, using 15,000 EUR for business development travel and legal fees for the licensing agreement. The remaining 10,000 EUR covers my living expenses during the transition to Denmark. The primary risk is visa processing delays, which I mitigate by beginning the application in Month 1 and maintaining remote work capability.

CHECKLIST

- [ ] Complete BII online application form at the BioInnovation Institute website
- [ ] Upload motivation letter as PDF
- [ ] Upload short essays as single PDF document
- [ ] Provide CV with full publication list and ORCID profile link
- [ ] Submit provisional patent filing number and date
- [ ] Provide two letters of recommendation from named collaborators (Berridge, Gershman, Daw, or Mattar)
- [ ] Submit proof of B.Pharm degree and transcript
- [ ] Provide evidence of open-source platform repositories on GitHub
- [ ] Submit a one-page budget breakdown for the 100,000 EUR request
- [ ] Provide a letter of intent from a Copenhagen incubator for virtual address and support
- [ ] Submit a timeline for Danish entity establishment
- [ ] Provide a copy of the pre-registration documents on OSF and Zenodo

EDITOR NOTES

- Eligibility risk: BII typically requires the venture to be incorporated or have a clear path to incorporation. The applicant must confirm whether BII accepts applications from unincorporated entities with a plan to incorporate within three months. If not, the application may need to be submitted through a partner incubator that acts as the legal applicant.
- Fact verification needed: The applicant states a provisional patent was filed in Q3 2026. The exact filing date, patent office, and application number must be confirmed and included in the application. The patent may not yet be published, so a copy of the filing receipt should be attached.
- Gap in profile: The applicant has not specified the exact amount requested from BII. The essays assume 100,000 EUR, but the actual BII pre-seed funding range should be verified from the programme guidelines. The budget breakdown must match the requested amount.
- Gap in profile: The applicant mentions two potential co-founders with EU residency but does not name them or provide evidence of their commitment. A brief letter of support from at least one co-founder should be included, or the applicant should explain the plan to recruit a co-founder after acceptance.
- Gap in profile: The applicant’s current employment as National Product Manager at Synthcare may conflict with the full-time commitment required by BII. The applicant should clarify whether they plan to leave this position or reduce to part-time if the BII grant is awarded.

AI Draft — BioInnovation Institute (BII)